FDA Approves First New Head and Neck Cancer Therapy in a Decade

The U.S. Food and Drug Administration has granted accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma. This marks the first new therapy for this patient population in ten years, offering a response rate more than double that of current standards. Johnson & Johnson announced the approval on November 5, 2026. The drug is a dual-targeted therapy for the EGFR and MET pathways, and this is its first indication outside of non-small cell lung cancer.

Currently approved therapies in this setting yield response rates of roughly 20% or lower. The FDA's Accelerated Approval Program allowed this decision based on surrogate endpoints, requiring confirmation of clinical benefit in an ongoing phase 3 trial. The approval was granted to Janssen Biotech, Inc.

Clinical benefit demonstrated in phase 1b/2 trial

The approval is based on data from the phase 1b/2 OrigAMI-4 trial, which enrolled 102 patients. The trial reported an overall response rate of 42%, with 15% of patients achieving a complete response and 28% achieving a partial response. This is more than double the typical response rate for existing therapies.

Among responders, 56% maintained a response for six months or longer. The median time to first response was 6.6 weeks. At a median follow-up of 11.8 months, median progression-free survival was 6.8 months and median overall survival was 12.5 months. Investigator-assessed data showed an overall response rate of 47%, and 84% of evaluable patients experienced shrinkage of their target lesions.

The trial population had a median age of 63.5 years. The racial breakdown was 45% Asian and 43% White. All patients had disease that progressed after platinum-based chemotherapy and immunotherapy. The indication specifically excludes patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Safety profile includes key risks and common adverse events

The drug's prescribing information carries several boxed warnings. These cover risks of hypersensitivity, interstitial lung disease, dermatologic and ocular toxicity, and fetal harm.

Common adverse effects, occurring in at least 20% of patients, were frequent. Rash was reported in 79% of patients. Other common events included fatigue, nail toxicity, stomatitis, and edema.

Serious adverse reactions occurred in 39% of patients. Fatal adverse reactions occurred in 6% of patients. These included sudden death, myocardial ischemia, tumor hemorrhage, aspiration pneumonia, and interstitial lung disease. Administration-related reactions occurred in 13% of patients, though all were low-grade. Only 8% of patients discontinued treatment due to treatment-related adverse events.

Regulatory pathway and ongoing confirmatory requirements

Continued approval for Rybrevant Faspro is contingent on verification of clinical benefit in the ongoing phase 3 OrigAMI-5 trial. This confirmatory study is evaluating the subcutaneous drug in combination with carboplatin and pembrolizumab as a first-line treatment.

The FDA had previously granted the therapy breakthrough therapy designation in February 2026 and priority review in July 2026. Angelo De Claro, M.D., a director in the FDA's Oncology Center of Excellence, stated, "Today’s approval represents a meaningful step forward for patients with head and neck squamous cell carcinoma."

The drug's mechanism targets both EGFR and MET, pathways overexpressed in 80% to 90% of recurrent or metastatic head and neck tumors. Dosing is weight-based, administered via subcutaneous injection. Patients receive an initial dose of 1600 mg or 2240 mg, followed by maintenance doses of 2400 mg or 3360 mg every three weeks.

Final confirmation of the therapy's benefit now rests with the ongoing OrigAMI-5 trial, which continues to enroll patients.